This suggests that proactive treatment in such elderly individuals with anti-amyloid antibodies, as in the AHEAD trial or TRAILBLAZER-ALZ3 (NCT05026866), or treatment targeting tau might help in preventing the progression of brain atrophy and cognitive decline. This evidence concerns the gene MAPT and Brain atrophy.